Metrics as of 10/14/2026, 08:32 AM (Berlin time), refresh in progress.
Ardelyx Stock
Ardelyx, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael G. Raab
- Employees
- 489
- Market cap
- $788 M
- IPO
- 19/06/2014
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its…
Ardelyx stock: price history
1D
+2.2%
1W
-2.1%
1M
-9.4%
6M
-49.4%
YTD
-45.3%
1Y
-36.3%
2Y
-46.7%
5Y
+195.4%
10Y
-0.6%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~32% stronger price swings than usual
Ask the agents about Ardelyx
Analyst assessment of Ardelyx
PRICE TARGET LOW
US$13.00
CONSENSUS
US$13.00
MEDIAN
US$13.00
PRICE TARGET HIGH
US$13.00
0
STRONG BUY
16
BUY
0
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 19/08/2026
Ardelyx stock metrics
P/E
-14.13
P/B
5.31
EV/EBITDA
-38.35
RETURN ON EQUITY
-11.2%
NET MARGIN
-13.8%
DEBT/EQUITY
1.72
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.0%
FLOAT SHARES
237,158,462
AVG. DAILY VOLUME (30D)
4,415,749
Insider transactions (SEC)
Williams Laura A
Williams Laura A
Williams Laura A
RAAB MICHAEL
RAAB MICHAEL
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +2.2%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Ardelyx stock
What does Ardelyx do?
Ardelyx, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael G. Raab, the company employs around 489 people.
The IPO was on 19/06/2014; the stock trades on NASDAQ under the ticker ARDX.
What do analysts say about Ardelyx stock?
16 analysts rate the stock, the consensus is Buy (as of 19/08/2026).
The average price target is US$13.00, ranging from US$13.00 to US$13.00, with a median of US$13.00.
This is an external assessment, not a statement by Market Jury.
When does Ardelyx report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 32% stronger than usual.
Does Ardelyx pay a dividend?
No, Ardelyx currently does not pay a dividend.
Which stocks are comparable to Ardelyx?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ardelyx stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ardelyx against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.